@article{c863e1f6a5564286ab58ce05d76b53bd,
title = "Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia",
author = "Ghobrial, \{I M\} and R Redd and P Armand and R Banwait and E Boswell and S Chuma and D Huynh and A Sacco and Roccaro, \{A M\} and A Perilla-Glen and K Noonan and M MacNabb and H Leblebjian and D Warren and P Henrick and Castillo, \{J J\} and Richardson, \{P G\} and J Matous and E Weller and Treon, \{S P\}",
note = "We examined the combination of the mammalian target of rapamycin inhibitor everolimus with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM) in a phase I/II study. All patients received six cycles of the combination of everolimus/rituximab or everolimus ...",
year = "2015",
month = jul,
day = "3",
doi = "10.1038/LEU.2015.164",
language = "American English",
volume = "29",
journal = "Leukemia",
number = "12",
}